Determining whether Organon & Co. (NYSE: OGN)—the global healthcare company spun off from Merck—is a good buy depends on an investor's focus on income stability versus growth. Analysts generally assign a consensus Hold rating, pointing to its attractive dividend distributions and established portfolio of women's health and biosimilar medications. However, cautious investors note slower revenue growth trends and debt management considerations, advising careful portfolio alignment.